So much discussion and debate about financial conflict of interest (FCOI) and how it might affect prescribing habits for physicians. There is a perception that manufacturers have significant impact on how oncologists select their treatments when caring for patients with cancer. To better understand and discuss this topic, I facilitated a discussion with Elias J. Jabbour, MD (of the MD Anderson Cancer Center) and S. Vincent Rajkumar, MD (of the Mayo Clinic)that was posted at Medscape.com. This roundtable discussion took place during the annual meeting of the American Society of Hematology (ASH) meeting in December 2019.
You can watch the discussion here.